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Abstract
Background: Gastric cancer peritoneal carcinomatosis is a common clinical problem, but there are no suitable
large animal models to study this problem. This study was to establish a stable rabbit peritoneal carcinomatosis
model of gastric cancer using VX2 tumor, and analyze the clinico-pathological features.
Methods: VX2 tumor was implanted into 36 New Zealand rabbits by 3 methods: laparotomic orthotopic injection
of cancer cells into the submucosal layer of the stomach (Group A), laparotomic implantation of tumor tissue into
the greater omentum immediately beneath the gastric antrum (Group B), and percutaneous injection of tumor
cells directly into the peritoneal cavity (Group C), 12 rabbits in each group. The animals were closely observed and
detailed clinico-pathological studies were conducted.
Results: The success rates of peritoneal carcinomatosis formation were 100% (12/12), 91.7% (11/12) and 58.3% (7/
12), respectively, for Groups A, B and C (P = 0.019, A versus C; P = 0.077, B versus C; P = 0.500, A versus B, Fisher’s
exact test). Two weeks after submucosal cancer cells injection in Group A, ulcerative gastric cancer with peritoneal
carcinomatosis showed typical VX2 tumor pathology, with widespread intraperitoneal metastatic nodules, bloody
ascites and perspicuous pulmonary metastases. The clinico-pathological progression pattern was very similar to
patients of advanced gastric cancer with peritoneal carcinomatosis. Groups B and C showed similar pattern of
cancer progression, but less aggressive.
Conclusions: First large animal model of peritoneal carcinomatosis from gastric cancer has been established by
laparotomic orthotopic injection of VX2 cancer cells into the submucosal layer of the stomach, providing a more
suitable model for surgical interventional studies. The clinico-pathological features of this model resemble human
peritoneal carcinomatosis.
Background
The loco-regional progression of gastrointestinal and
gynecological cancers frequently results in peritoneal
carcinomatosis (PC), which is characterized by the pre-
sence of tumor nodules of various size, number and dis-
tribution on the peritoneal surface, with very poor
prognosis and a median survival of less than 6 months
[1,2]. Current treatments for such PC are systemic che-
motherapy, best support care and palliative therapy,
with no hope of cure. In order to tackle this problem, a
new treatment modality called cytoreductive surgery
(CRS) plus hyperthermic intraperitoneal chemotherapy
(HIPEC) has been developed over the past two decades,
taking advantages of surgery to reduce visible tumor
burden, and regional hyperthermic chemotherapy to
eradicate micrometastases [3-6].
While clinical studies have made progresses, some
experimental animal PC models have also been devel-
oped, including mice models and rat models to evaluate
the efficacy and adverse effects of experimental HIPEC
protocols [7-10]. Although such small animal models
are useful in experimental studies, it is technically diffi-
cult to perform operations on small animals because of
the little body size and delicate hemodynamic condi-
tions. Large animal such as pig has also been used to
test the pharmacokinetics of HIPEC, but the animals
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Therefore, a large animal PC model more suitable for
surgical interventional studies is desirable. Here we
report on a rabbit PC model from gastric cancer, with
clinico-pathological features mimic patients with
advanced gastric cancer.
Methods
Animals
Thirty six New Zealand white rabbits, 18 males and 18
females, body weight between 2.5~3.0 kg, were obtained
from Animal Biosafety Level 3 Laboratory at the Animal
Experimental Center of Wuhan University (Animal
Study Certificate SCXK 2003-0004). The animals were
individually housed and allowed free access to standard
laboratory food and water as well as 12 h of light and
dark cycle per day. The animal study protocol was
approved by the Animal Welfare Committee of the
Center.
Tumor strain and tumor cell preparation
Rabbit VX2 carcinoma was used to establish gastric can-
cer with PC in this study. The VX2 tumor is a trans-
plantable rabbit squamous cell carcinoma, characterized
by rapid tumor growth and early metastasis, established
f r o mav i r u s - i n d u c e dp a p i l l o m ab yR o u sa n dc o w o r k e r s
[12]. The tumor was maintained by successive in vivo
transplantation into the hind leg of 2 carrier rabbits
used for every passage.
When the VX2 tumor grew to about 1 cm in diameter
on the carrier rabbit, the animal was anesthetized by ear
vein injection of 3% pentobarbital sodium (30 mg/kg).
After skin preparation and disinfection, the tumor was
excised from the carrier rabbit and placed in icy cold
0.9% sodium chloride solution. Tumor tissue was
minced into approximately 1.0~2.0 mm
3 fragments and
suspended in 2 mL of normal saline, then drawn into a
2m Li n j e c t o r .O t h e rt u m o rtissues about 3.0~5.0 mm
3
were placed into the homogenizer embedded in ice
b a t h ,t ow h i c h3m Lo fi c yc o l dn o r m a ls a l i n ew a s
added, and the tumor cells suspension was made, with
the tumor cells concentration adjusted to 5×10
10 vial
cells/L.
Construction of gastric cancer with PC
All rabbits had overnight fasting before experiment, but
water was given ad libitum. After randomization, the
animals were anesthetized by ear vein injection of 3%
pentobarbital sodium (30 mg/kg). The abdominal skin
was cleaned and disinfected. Three approaches were
adopted to construct rabbit models of PC, 12 animals
for each group. Group A of submucosal tumor cell
inoculation: A midline incision of 3 cm long was made
beginning 2 cm below the xyphoid and the upper
abdomen was open. The stomach was exposed, 0.1 mL
of tumor cells (5×10
10 vial cells/L) was injected into the
submucosal layer of the stomach (Figure 1), through the
serosal layer and the muscle layer, the injection site was
pressed for 1 min to keep the injected tumor cells in
place, and the abdomen was closed with a double layer
3-O vicryl interrupted suture. Group B of tumor tissue
implantation: The incision was the same as in Group A.
When the stomach was exposed, a small piece of fresh
tumor tissue about 1.0 mm
3 was implanted into the
greater omentum immediately beneath the gastric
antrum, and the wound was closed. Group C of percuta-
neous injection of tumor cells: After skin preparation,
0 . 1m Lo ft u m o rc e l l s( 5 × 1 0
10 vial cells/L) was directly
injected into the upper abdominal cavity, and the injec-
tion site was pressed for 1 min. After tumor inoculation,
penicillin G at the dose of 100,000 IU/d was intramus-
cularly injected to each animal for 3 days. All the ani-
mals were give intravenous fluid rehydration with
100 mL of 0.9% normal saline solution.
Animal observation and pathological studies
After operation, daily observation was made on each
rabbit to check food intake, activities, and any abnorm-
a l i t i e ss u c ha sd i a r r h e aa nd dehydration. The body
weight was measured every 3 days and the natural his-
tory of the disease progression was recorded. In order to
obtain a detailed description of the progressive develop-
ment of gastric cancer PC, euthanasia was performed on
3 rabbits in Group A at the end of weeks 1, 2, 3 and 4,
by overdose injection of 3% pentobarbital sodium
through the ear vein. For animals in Groups B and C,
euthanasia was also performed when the animals
showed obvious signs of distress and waste, in keeping
with UKCCCR guidelines for the welfare of animals in
experimental neoplasia [13]. Post mortem pathological
examinations included gross pathology such as tumor
size and distributions; local tumor features of gastric
cancer including ulcer formation, obstruction and per-
foration; special features of peritoneal carcinomatosis
such as bloody ascites, discrete or confluent tumor
nodules on the peritoneum, cancerous changes in the
greater omentum and intestinal obstructions; metastases
to major organs such as the liver, adrenal glands, pan-
creas and the lungs. All the suspected organ tissues
were sampled for routine histopathology study with sec-
tions stained by hematoxylin and eosin (HE stain).
Statistical analysis
T h eb o d yw e i g h ta n dt u m o rw e i g h tw e r ee x p r e s s e da s
mean ± standard deviation (M ± SD). The intra-abdom-
inal metastases and bloody ascites were recorded as
ranges and medians. The SPSS statistical software pack-
age version 10.0 (SPSS Inc., Chicago Il, USA) was used
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sidered as statistically significant.
Results
Success of PC model construction
Of 36 animals used for PC model construction, the
operation was successful in 33 rabbits and 3 animals
died 3 days after operation. Of the 3 deaths, 1 rabbit in
Group C died of diffused peritonitis on day 3 because
the percutaneous injection was mistakenly into the
small intestine; and 1 rabbit each in Groups B and C
died of congestive heart failure on day 2 because of fast
fluid rehydration. Another 3 rabbits in Group C did not
develop PC for unknown reasons. The success rates
were 100% (12/12) in Group A, 91.7% (11/12) in Group
B and 58.3% (7/12) in Group C (P = 0.019, A versus C;
P = 0.077, B versus C; P = 0.500, A versus B, Fisher’s
exact test).
Tumor growth and its impact on the animal
After cancer cells injection into the gastric submucosa
in Group A, the tumor demonstrated accelerated
growth. The tumor sizes were (0.028 ± 0.012) cm
3,
(1.183 ± 0.148) cm
3 and (7.706 ± 1.629) cm
3, respec-
t i v e l y ,a tt h ee n do fw e e k s1 ,2 ,a n d3 .T h ea n i m a l s
showed progressive decrease in body weight, from
(2.48 ± 0.21) kg before operation to (2.45 ± 0.21) kg on
week 1, (2.24 ± 0.19) kg on week 2, (2.02 ± 0.18) kg on
week 3 and (1.81 ± 0.1) kg on week 4. Along with body
weight changes, the feeding and general health status of
the animals deteriorated progressively.
Growth characteristics of peritoneal carcinomatosis in
animal model
Tumor characteristics in Group A were carefully
recorded. One week after submucosa injection of cancer
cells, many small, hard and transparent nodules began
to develop on the greater omentum and the antrum of
the stomach. No ascites was observed. Two weeks later,
nodules on the greater omentum began to merge into
confluent masses without discernable demarcations with
the stomach. The mass on the gastric wall grew bigger
and protruded into the stomach cavity to form typical
ulcerative cancer (Figure 2). There was about 5 mL of
Figure 1 Construction of rabbit peritoneal carcinomatosis model from gastric cancer. When the rabbit stomach was exposed under
general anesthesia, a 16 G needle was inserted through the serosal and muscle layers into the submucosal layer of the stomach, and 0.1 mL of
tumor cells (5×10
10 vial cells/L) were injected, and injection site was pressed for 1 min to keep the tumor cells in place (See the text for detailed
description).
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later, many nodules began to form in the mesentery and
the retroperitoneum. The confluent mass on the greater
omentum began to invade the liver and encase the sto-
mach (Figure 3). Often the stomach mass and the
greater omentum mass merged into one big tumor
block. Bloody ascites could reach as much as 100 mL.
There was also some fluid accumulation in the pericar-
dium. Many nodules were seen on the abdominal wall.
No nodules were observed in the lungs. Four weeks
later, numerous tumor nodules were observed in the
lungs, the liver, adrenal glands, small intestine, trans-
verse colon and the bladder. The abdominal wall was
totally invaded by the tumor. Tumors in Groups B and
C showed similar growth characteristics.
Histopathological characteristics of VX2 rabbit PC
All investigated tumor specimens showed extensive
invasive growth and tissue destruction. The tumors, on
the greater curvature of the gastric antrum, penetrated
the mucosal layer to form ulcers. Microscopic view
could find cancer nests penetrating the whole stomach
wall, with typical invasion into the muscle layer and the
gastric glands (Figure 4A). The tumor cells are round,
oval or atypical morphology with many pathological
mitotic figures (Figure 4B). There were also conspicuous
lymphocytes, plasma cells and other inflammatory cells
infiltration.
Major features of this rabbit model of PC from gastric
cancer could be summarized in Table 1.
Discussion
PC represents a serious clinical challenge in the treat-
ment of gastrointestinal and gynecological cancers. In
gastric cancer, PC is a frequent event with 15% to 50%
or more patients having PC at the surgical exploration,
especially when there is serosal involvement by the
tumor [14-16]. Even after curative resection of gastric
Figure 2 Rabbit gastric cancer in group A. Two weeks after submucosal inoculation of VX2 tumor cells, pathological study after animal
euthanasia shows typical ulcerative gastric cancer (arrow) in New Zealand rabbit.
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recurrence. A Korean study in 500 gastric cancer
patients treated by standardized radical gastrectomy and
lymphadectomy, found that within 5 years post gastrect-
omy, PC is the most frequent pattern (51.7%) of cancer
recurrence [17]. Another randomized prospective study
in Japan also found peritoneal recurrence is the most
frequent event (15.8%) at 3 years in 530 patients treated
with highly standardized curative gastrectomy [18]. A
prospective Italian study in 200 patients found that, at
the mean follow-up of 42.3 months, PC accounted for
32.9% of recurrence [19]. Another Italian study with 441
Figure 3 Rabbit PC model of gastric origin from Group A. Three weeks after VX2 carcinoma cells were injected into the submucosal layer of
the stomach, confluent tumor mass on the greater omentum encased stomach wall (black arrow) and the liver (yellow arrow).
Figure 4 Histopathology of rabbit model gastric cancer with PC, 2 weeks after VX2 carcinoma cells were injected into the submucosal
layer of the stomach in Group A. VX2 tumor cells invaded the whole stomach wall (4A, ×100, HE stain) and showed many pathological
mitotic figures (4B, ×200, HE stain).
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median follow-up of 48 months [20]. Therefore, syn-
chronous and metachronous PC is the most important
problem of gastric cancer recurrence and metastasis.
Such gastric PC is associated with poor prognosis with
median survival ranging from 1-1.6 months [21,22] to
3.1-9 months [1,15]. As is rightly stated, the risk of peri-
toneal recurrence of gastric cancer is particularly high in
patients with diffuse-mixed tumors and infiltration of
the serosa, against which surgery alone, no matter how
radical, can offer little possibility of a cure [20]. There-
fore, new comprehensive treatment strategies are
required.
Clinical studies suggest that CRS plus HIPEC could
achieve good efficacy in selected patients with PC. To
our knowledge there are 4 institutional studies on CRS
plus HIPEC in patients with gastric cancer, 2 retrospec-
tive (42 and 26 patients, respectively) [3,23], 1 prospec-
tive (49 patients) [4] and 1 comparative non-randomized
(34 patients) studies [24]. The median survival ranged
from 6.6 months [24], 8 months [23] to 10-11 months
[3,4], and the 5-year survival ranged from 6% [3,25] to
16% [4]. These clinical studies are based on non-homo-
genous and non-standardized groups of patients. In
order to more objectively evaluate such treatment, it is
necessary to study this treatment modality under experi-
mental conditions.
Small animal models of PC have been established,
including nude mice models and rat models [26-29]. In
most of these animal models, cancer cells are injected
directly into the peritoneum, which will result in wide-
spread PC in due time [25,30-32]. All these small animal
models are only suitable for HIPEC alone because the
small body size and limited blood supply cannot stand
major surgical interventions. The establishment of large
animal model of PC from gastric cancer is necessary for
experimental studies testing CRS and HIPEC.
VX2 carcinoma is a rabbit tumor of epithelial origin,
established from a virus-induced papilloma by Rous and
coworkers [12]. Characterized by rapid tumor growth
and early metastasis, this tumor is extremely malignant
and can be allogeneously transplanted almost anywhere
in rabbits. Although VX2 is a squamous cell carcinoma
model, which may be different from adenocarcinoma, it
has been used in many experimental studies on head
and neck cancer [33-36], lung cancer [37], esophageal
cancer [38,39], breast cancer [40], gastric cancer [41,42],
liver cancer [43,44], colon cancer [45,46], kidney cancer
[47-49], bladder cancer [50], bone tumor [51] and sim-
ple peritoneal carcinomatosis [52]. In this study we con-
structed a rabbit model of gastric cancer with PC. Our
results demonstrated that the orthotopic inoculation of
tumor cells into the stomach is the most appropriate
method, resulting in typical ulcerative gastric cancer
and progressive PC, all features similar to the clinico-
pathologic progression of gastric cancer patients. In
comparison, percutaneous injection of cancer cells into
the abdominal cavity could result in intestinal injury by
mistake. No ulcerative gastric cancer could be induced,
and the tumor take rate is low. These results support
the notion that orthotopic tumor model is preferred for
the study of tumor biological behaviors and interven-
tions [53]. The natural history of this model is about 4
weeks, including a subclinical stage in the first week,
clinical stage in the second week, accelerated PC stage
in the third week and terminal stage in the fourth week.
Typical PC features are peritoneal cancer nodules of
various sizes throughout the whole abdominal cavity,
“omentum cake”, intestinal obstruction and bloody
ascites. The end of the first week could be considered
as the early PC, while the end of the second week as
the advanced PC. Therefore, specific treatment
approaches could be designed to target either early PC
or advanced PC.
Table 1 Tumor characteristics of three different inoculation approaches
Group A Group B Group C
Technical
feature
Laparotomic orthotopic
tumor cell injection into the gastric submucosa
Laparotomic orthotopic
tumor tissue inoculation
beneath the gastric antrum
Percutaneous tumor cell injection
into the peritoneum
Success rate 100% (12/12) 91.7% (11/12) 58.3% (7/12)
Major
pathological
events
Rapid tumor progression resulting in respiratory distress
syndrome, diffused peritonitis due to perforation of gastric
tumor, intestinal obstruction, renal failure
Rapid tumor progression
resulting in intestinal
obstruction, renal failure
Rapid tumor progression resulting
in intestinal adhesion an
obstruction, renal failure
Gross
pathology
Ulcerative gastric cancer with PC, ascites Ulcerative gastric cancer with
PC, ascites
PC without gastric ulcer, ascites
Histopathology Penetrating growth of cancer cell nests invading surrounding
structures, tumor necrosis in the central zone of the tumor
mass
Advantages Most resemble clinical gastric cancer with PC Technically less difficult Technically easy
Disadvantages Technically difficult Not exactly mimic gastric
cancer with PC
Mistaken injection into the
intestines
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A rabbit model of gastric cancer with PC has been
established by injecting VX2 cancer cells into the sub-
mucosal layer of the stomach. The model is character-
ized by typical ulcerative gastric cancer with progressive
PC, making it more suitable for surgical interventional
studies to evaluate CRS and HIPEC against gastric PC.
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